Metabolic effects of calcium antagonists in humans, with emphasis on carbohydrate, lipid, potassium, and uric acid homeostases.

@article{Trost1988MetabolicEO,
  title={Metabolic effects of calcium antagonists in humans, with emphasis on carbohydrate, lipid, potassium, and uric acid homeostases.},
  author={Bernhard N. Trost and Prof. P. Weidmann},
  journal={Journal of cardiovascular pharmacology},
  year={1988},
  volume={12 Suppl 6},
  pages={
          S86-92
        }
}
Since metabolic side effects of conventional antihypertensive drugs could be one reason for the lack of improvement of cardiac morbidity and mortality, metabolic neutrality has become an important postulate of newer products such as the calcium antagonists (CA). Carbohydrate homeostasis--in spite of an anticipated deterioration derived from early in vitro experiments--has mostly been unaffected by CA therapy in humans, nondiabetic and diabetic. This was found in long-term studies in particular… 

Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems

L Laboratory studies confirm the effects of thiazides and β-adrenergic antagonists on glucose and lipid metabolism, and suggest that compensatory activation of the SNS and RAS may be one mechanism.

Antihypertensive and hypouricaemic effects of nitrendipine in chronic renal failure

Compared to placebo, nitrendipine decreased supine BP and upright BP and lowered plasma uric acid excretion; glucose, insulin, serum total lipids, and lipoprotein fractions were unchanged; and plasma and whole blood volume, plasma angiotensin II and creatinine concentrations, and urinary electrolyte and Creatinine excretion were not significantly changed.

Effect of Amlodipine on Insulin Secretion, Glucose, Lipid Profile and Urinary Albumin Excretion in Patients with Mild Hypertension and Non-Insulin-Dependent Diabetes

Results suggest a renoprotective role for amlodipine in this setting, an effective antihypertensive agent that has no negative long term effect on glucose homeostasis, β-cell secretion or lipid profile in patients with mild hypertension and NIDDM.

Antihypertensive agents, serum lipoproteins and glucose metabolism.

Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension

Long-term treatment with amlodipine does not affect insulin sensitivity, circulating insulin or glucose, or lipoprotein metabolism in obese, non-diabetic patients with essential hypertension.

Requirements for antihypertensive therapy in diabetic patients: metabolic aspects

  • A. TeuscherP. Weidmann
  • Medicine
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension
  • 1997
Treatment of diabetics with thiazides should be avoided until the influence of these agents on prognosis is clarified, and the combination of an ACE inhibitor and a calcium antagonist that lowers the heart rate might offer even greater advantages than either class of drug alone.

Swiss Hypertension Treatment Programme with Verapamil and/or Enalapril in Diabetic Patients

In hypertensive patients with diabetes, a diuretic-free therapy based on the calcium antagonist verapamil or the ACE inhibitor enalapril, alone or combined, can effectively decrease BP without adversely affecting carbohydrate and lipid metabolism.

Hypertension in the Diabetic Patient

Optimal antihypertensive drug therapy of patients with both disorders is therefore based on limited experimental data, practical experience and educated guesswork, and needs to be tailored to each (often multimorbid) individual.